a woman who is in lactation period or who may be pregnant, or those who do not agree to prevent pregnancy by medically appropriate means for up to 7 days after study drug administration. medically appropriate contraception means that using a combination of two or more of the following: not having sexual intercourse, taking surgical sterilization such as vasectomy or intrauterine device, taking oral contraceptive, using condom. a person who has severe liver damage (ast or alt at the time of qualification test is more than 3 times the upper limit of institutional standard and total bilirubin is more than twice the upper limit of institutional standard value), renal disorder (egfr of eligibility test value 30 ml/min/1.73m2 or less). a person with hypersensitivity to ivermectin. a person with a history of severe drug allergies such as stevens-johnson syndrome, toxic epidermal necrolysis. a person who has received the prohibited medication within the past month (within the past 6 months for biologics), or those who need to use the prohibited medication during the clinical trial period. those who are scheduled to receive sars-cov-2 vaccination from the date of consent to the end of the follow-up period. a person who are currently participating in other clinical trials or who have participated in other clinical trials within 30 days before obtaining consent. in addition, a person who is determined to be unsuitable as a subject of this clinical trial by the principal investigator."

a woman who is in lactation period or who may be pregnant, or those who do not agree to prevent pregnancy by medically appropriate means for up to 7 days after study drug administration. medically appropriate contraception means that using a combination of two or more of the following: not having sexual intercourse, taking surgical sterilization such as vasectomy or intrauterine device, taking oral contraceptive, using condom. a person who has severe liver damage (ast or alt at the time of qualification test is more than 3 times the upper limit of institutional standard and total bilirubin is more than twice the upper limit of institutional standard value), renal disorder (egfr of eligibility test value 30 ml/min/1.73m2 or less). a person with hypersensitivity to ivermectin. a person with a history of severe drug allergies such as stevens-johnson syndrome, toxic epidermal necrolysis. a person who has received the prohibited medication within the past month (within the past 6 months for biologics), or those who need to use the prohibited medication during the clinical trial period. those who are scheduled to receive sars-cov-2 vaccination from the date of consent to the end of the follow-up period. a person who are currently participating in other clinical trials or who have participated in other clinical trials within 30 days before obtaining consent. in addition, a person who is determined to be unsuitable as a subject of this clinical trial by the principal investigator."

1. a woman who is in lactation period or who may be pregnant, or those who do not agree to prevent pregnancy by medically appropriate means for up to 7 days after study drug administration. medically appropriate contraception means that using a combination of two or more of the following: not having sexual intercourse, taking surgical sterilization such as vasectomy or intrauterine device, taking oral contraceptive, using condom. 2. a person who has severe liver damage (ast or alt at the time of qualification test is more than 3 times the upper limit of institutional standard and total bilirubin is more than twice the upper limit of institutional standard value), renal disorder (egfr of eligibility test value 30 ml/min/1.73m2 or less). 3. a person with hypersensitivity to ivermectin. 4. a person with a history of severe drug allergies such as stevens-johnson syndrome, toxic epidermal necrolysis. 5. a person who has received the prohibited medication within the past month (within the past 6 months for biologics), or those who need to use the prohibited medication during the clinical trial period. 6. those who are scheduled to receive sars-cov-2 vaccination from the date of consent to the end of the follow-up period. 7. a person who are currently participating in other clinical trials or who have participated in other clinical trials within 30 days before obtaining consent. 8. in addition, a person who is determined to be unsuitable as a subject of this clinical trial by the principal investigator."

1. a woman who is in lactation period or who may be pregnant, or those who do not agree to prevent pregnancy by medically appropriate means for up to 7 days after study drug administration. medically appropriate contraception means that using a combination of two or more of the following: not having sexual intercourse, taking surgical sterilization such as vasectomy or intrauterine device, taking oral contraceptive, using condom. 2. a person who has severe liver damage (ast or alt at the time of qualification test is more than 3 times the upper limit of institutional standard and total bilirubin is more than twice the upper limit of institutional standard value), renal disorder (egfr of eligibility test value 30 ml/min/1.73m2 or less). 3. a person with hypersensitivity to ivermectin. 4. a person with a history of severe drug allergies such as stevens-johnson syndrome, toxic epidermal necrolysis. 5. a person who has received the prohibited medication within the past month (within the past 6 months for biologics), or those who need to use the prohibited medication during the clinical trial period. 6. those who are scheduled to receive sars-cov-2 vaccination from the date of consent to the end of the follow-up period. 7. a person who are currently participating in other clinical trials or who have participated in other clinical trials within 30 days before obtaining consent. 8. in addition, a person who is determined to be unsuitable as a subject of this clinical trial by the principal investigator."

1. a woman who is in lactation period or who may be pregnant, or those who do not agree to prevent pregnancy by medically appropriate means for up to 7 days after study drug administration. medically appropriate contraception means that using a combination of two or more of the following: not having sexual intercourse, taking surgical sterilization such as vasectomy or intrauterine device, taking oral contraceptive, using condom. 2. a person who has severe liver damage (ast or alt at the time of qualification test is more than 3 times the upper limit of institutional standard and total bilirubin is more than twice the upper limit of institutional standard value), renal disorder (egfr of eligibility test value 30 ml/min/1.73m2 or less). 3. a person with hypersensitivity to ivermectin. 4. a person with a history of severe drug allergies such as stevens-johnson syndrome, toxic epidermal necrolysis. 5. a person who has received the prohibited medication within the past month (within the past 6 months for biologics), or those who need to use the prohibited medication during the clinical trial period. 6. a person who are currently participating in other clinical trials or who have participated in other clinical trials within 30 days before obtaining consent. 7. in addition, a person who is determined to be unsuitable as a subject of this clinical trial by the principal investigator."

1. a woman who is in lactation period or who may be pregnant, or those who do not agree to prevent pregnancy by medically appropriate means for up to 7 days after study drug administration. medically appropriate contraception means that using a combination of two or more of the following: not having sexual intercourse, taking surgical sterilization such as vasectomy or intrauterine device, taking oral contraceptive, using condom. 2. a person who has severe liver damage (ast or alt at the time of qualification test is more than 3 times the upper limit of institutional standard and total bilirubin is more than twice the upper limit of institutional standard value), renal disorder (egfr of eligibility test value 30 ml/min/1.73m2 or less). 3. a person with hypersensitivity to ivermectin. 4. a person with a history of severe drug allergies such as stevens-johnson syndrome, toxic epidermal necrolysis. 5. a person who has received the prohibited medication within the past month (within the past 6 months for biologics), or those who need to use the prohibited medication during the clinical trial period. 6. a person who are currently participating in other clinical trials or who have participated in other clinical trials within 30 days before obtaining consent. 7. in addition, a person who is determined to be unsuitable as a subject of this clinical trial by the principal investigator."